{"id":"W3028905201","doi":"10.1200/jco.2020.38.15_suppl.8015","title":"Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Medicine; Lenalidomide; Bendamustine; Internal medicine; Chronic lymphocytic leukemia; Hazard ratio; Progression-free survival; Gastroenterology; Rituximab; Oncology; Leukemia; Multiple myeloma; Overall survival; Confidence interval; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.007824249,0.0007957148,0.005623849,0.0005852086,0.0001618885,0.00006563799,0.001420669,0.002151517,0.001204791],"category_scores_gemma":[0.05309672,0.0006108326,0.001360674,0.001398272,0.001324813,0.0004492471,0.0007183953,0.006852961,0.0006985156],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.1620735,"about_ca_system_score_gemma":0.3018237,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008658443,"about_ca_topic_score_gemma":0.0006628822,"domain_scores_codex":[0.984237,0.001412127,0.008816713,0.001313181,0.00245093,0.001770083],"domain_scores_gemma":[0.9779923,0.0135811,0.003729617,0.001035861,0.001107585,0.002553552],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6664007,0.00388743,0.0002618481,0.001241977,0.001910113,0.06312366,0.00125272,0.007606831,0.0005341446,0.000317364,0.1492665,0.1041967],"study_design_scores_gemma":[0.6372179,0.05114371,0.001887011,0.0008954628,0.0009104201,0.003255026,0.0004633274,0.09245481,0.000183535,0.00008706217,0.2108614,0.000640335],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.954044,0.004955889,0.0003066007,0.02018968,0.005425466,0.001566734,0.0001121009,0.0001680886,0.01323137],"genre_scores_gemma":[0.9793689,0.003808603,0.00286015,0.004361996,0.007772523,0.00002644015,0.00005367438,0.0001580459,0.001589691],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1397502,"threshold_uncertainty_score":0.9997082,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2755138791443671,"score_gpt":0.4800903293985233,"score_spread":0.2045764502541561,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}